Tuesday, August 11, 2026

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

›
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company developing a...

Assessing airway clearance dysfunction in Friedreich's ataxia: A focus on peak cough flow

›
Smith BK, Coker MA, Liberati C, Meyer BP, Norman S, Ehrbar J, Leon-Astudillo C, Subramony S, Corti M. Assessing airway clearance dysfunction...

Impaired Glur2 palmitoylation in cerebellar Purkinje cells of a Friedreich ataxia mouse model

›
Elizabeth Mercado-Ayón, Jennifer Coulman, Jia-Ying Lee, Eunjoo Lancaster, Elliot Goga, Mohammad Asad, Eric Witze, David R. Lynch, Impaired G...
Saturday, August 8, 2026

Partial bypass of frataxin deficiency by ISCU M141I restores cytosolic and nuclear Fe–S cluster assembly

›
Mosbach, V., Maio, N., Hermet, L. et al. Partial bypass of frataxin deficiency by ISCU M141I restores cytosolic and nuclear Fe–S cluster ass...

Autophagy activation by urolithin-a derivative UA-36 mitigates Friedreich's ataxia pathologies induced by frataxin deficiency

›
Gong Q, Liu T, Han X, Zhang R, Liu X, Xiong B, Ali T, Huang J, Xie Y, Li S, Yang X. Autophagy activation by urolithin-a derivative UA-36 mit...
Wednesday, August 5, 2026

Visual Pathways Involvement in Friedreich’s Ataxia Patients Without Macular Impairment

›
Parisi, V.; Barbano, L.; Di Renzo, A.; Dell’Aquila, C.; D’Andrea, M.; Castelluzzo, A.M.; Colacino, G.; Gioiosa, V.; Coppola, G.; Casali, C.;...

BRD4 recruitment into HP1 condensates desilences transcription without erasure of repressive chromatin

›
Brandon, C.J., Robinson-Thiewes, S., Kaulage, M. et al. BRD4 recruitment into HP1 condensates desilences transcription without erasure of re...

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

›
BALA CYNWYD, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar). “Open label (OL) study data announced in June furt...
Tuesday, August 4, 2026

Stem Cell Transplantation in Friedreich Ataxia: Cure for Leukemia but No Effect on Neurological Progression

›
A. Gitman, N. Bhandari, M. Castellaro, K. Schadt, M. Cancio, and D. R. Lynch, “ Stem Cell Transplantation in Friedreich Ataxia: Cure for Leu...

Adjuvia Therapeutics Closes $8 Million Series Seed Financing to Advance Novel Mitochondrial Disease Therapy into the Clinic

›
Jul 29, 2026. SAN FRANCISCO--(BUSINESS WIRE)--Adjuvia Therapeutics, a biotechnology company developing therapeutics to treat mitochondrial d...